CD274 and non-small cell lung carcinoma: In recent years, the update of many RCTs in treatment naïve metastatic NSCLC patients has shown that only <15% of patients with PD-L1 ≥ 50%17 and <10% of patients with any PD-L1 expression18,19 receiving PD-1/PD-L1 inhibitors alone or in combination with PCT are alive without progression at 5 years, being potentially cured by ICI treatment.